Basilea Pharmaceutica AG (BPMUF) Stock Price & Analysis
Basilea Pharmaceutica AG (BPMUF) — price $84.00 (0.00%), as of the Nov 18, 2026 trading session; market cap $1.04B.
Educational signal · not a buy or sell recommendation · How to read this
Basilea Pharmaceutica AG · BPMUF
Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company focused on developing products in oncology and anti-infectives. Its key products include Cresemba, an antifungal, and Zevtera, an antibiotic, with ongoing clinical trials to expand their applications and market reach.
Price as of Nov 18, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $84.00 | |
| Change on the day | 0.00% | |
| 52-week range | $59.29 – $84.00 | |
| Market capitalisation | $1.04B | |
| Price / earnings (trailing) | 16.88 | |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for Basilea Pharmaceutica AG (BPMUF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Basilea Pharmaceutica AG (BPMUF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Basilea Pharmaceutica AG (BPMUF) is the company analyzed here. It employs 189 people and is led by David Veitch. In Q2 FY2026 it reported revenue of CHF 118M and net income of CHF 28M. The market values it at $1.04B.
What do the latest results show for Basilea Pharmaceutica AG (BPMUF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CHF 118M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CHF 118M | CHF 28M | CHF 2.01 (diluted) |
| Q4 FY2025 | CHF 129M | CHF 24M | CHF 2.00 (diluted) |
| Q2 FY2025 | CHF 104M | CHF 16M | CHF 1.26 (diluted) |
| Q4 FY2024 | CHF 132M | CHF 57M | CHF 4.20 (diluted) |
What are the financial strengths and risks for Basilea Pharmaceutica AG (BPMUF)?
Short answer · as of
The distress and quality screens read Altman Z 2.31 · Piotroski F 8. Trailing ratios: ROE 36.1% · ROA 17.6% · current ratio 6.60 · earnings yield 5.8% · free-cash-flow yield 6.1%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BPMUF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BPMUF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: BPMUF Stock
These answers are editorial: 1 of these 8 answers is drawn from the BPMUF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is BPMUF a good stock to buy?
Stock Expert AI does not rate BPMUF buy, sell or hold. Basilea Pharmaceutica AG has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BPMUF stock price today?
The last price recorded for Basilea Pharmaceutica AG (BPMUF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for BPMUF?
The main risks for Basilea Pharmaceutica AG include the potential for clinical trial failures, which could significantly impact the company's pipeline and future revenue prospects. Regulatory hurdles and delays in obtaining approvals for new drugs also pose a risk.
What are the key factors to evaluate for BPMUF?
Evaluate BPMUF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Development of Lisavanbulin as a Tumor Checkpoint Controller: Lisavanbulin, a tumor checkpoint controller drug, represents a novel approach to cancer treatment. Not financial advice.
How frequently does BPMUF data refresh on this page?
BPMUF's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BPMUF's recent stock price performance?
Basilea Pharmaceutica AG (BPMUF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in oncology and anti-infectives. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BPMUF overvalued or undervalued right now?
The trailing P/E of Basilea Pharmaceutica AG (BPMUF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BPMUF before investing?
Before investing in Basilea Pharmaceutica AG (BPMUF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com